{"gene":"FECH","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1975,"finding":"Ferrochelatase (heme synthetase) catalyzes the terminal step of heme biosynthesis—chelation of ferrous iron with porphyrin—and its activity is markedly deficient in liver and cultured skin fibroblasts of patients with erythropoietic protoporphyria, establishing deficient ferrochelatase as the primary enzymatic defect in protoporphyria.","method":"Radiochemical enzyme assay using 59Fe and deuteroporphyrin/protoporphyrin as substrates in liver biopsies and skin fibroblast sonicates","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay, replicated across liver and fibroblast tissues from multiple patients vs. controls","pmids":["1184741"],"is_preprint":false},{"year":2001,"finding":"Human ferrochelatase is a homodimeric (86 kDa) mitochondrial membrane-associated enzyme whose 2.0 Å crystal structure reveals two [2Fe-2S] clusters, a 12-residue hydrophobic lip mediating membrane association that also forms the entrance to the active site pocket, and a conserved active site geometry supporting a catalytic model for ferrous iron insertion into protoporphyrin IX to form heme.","method":"X-ray crystallography at 2.0 Å resolution using single-wavelength iron anomalous scattering","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional interpretation supported by prior biochemical studies","pmids":["11175906"],"is_preprint":false},{"year":2001,"finding":"The penetrance of dominant erythropoietic protoporphyria is modulated by a hypomorphic FECH allele: an intronic SNP (IVS3-48T/C) activates an aberrant splice acceptor site, generating a misspliced mRNA that is degraded by nonsense-mediated decay (NMD), thereby reducing steady-state FECH mRNA and enzyme levels below the threshold required for clinical expression.","method":"Haplotype segregation analysis, identification of aberrant splice site usage, NMD mechanism characterization","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 — molecular dissection of splicing mechanism plus NMD, independently replicated in subsequent studies","pmids":["11753383"],"is_preprint":false},{"year":2004,"finding":"Human frataxin (holofrataxin) is a high-affinity iron-binding partner of ferrochelatase that directly delivers ferrous iron to ferrochelatase to mediate the terminal step of mitochondrial heme biosynthesis; distinct binding affinities of holofrataxin for ferrochelatase versus the ISU scaffold protein allow discrimination between heme and iron-sulfur cluster biosynthesis pathways.","method":"Protein–protein interaction (pulldown/reconstitution), iron delivery assay in vitro, affinity measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of iron delivery with binding-affinity characterization","pmids":["15123683"],"is_preprint":false},{"year":2011,"finding":"The transcription factor c-Myc regulates FECH gene expression by binding to E-boxes in the FECH promoter; 5-aza-2'-deoxycytidine demethylates these E-box-containing CpG sites and promotes nuclear translocation of c-Myc and its heterodimerization with Max, thereby increasing FECH transcription, heme biosynthesis, and erythroid differentiation.","method":"Promoter methylation analysis, ChIP, nuclear fractionation, siRNA knockdown in erythroid cell models","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, methylation analysis, nuclear translocation) in a single lab","pmids":["21903580"],"is_preprint":false},{"year":2020,"finding":"The Ras/MEK signaling pathway suppresses FECH activity through a HIF-1α-dependent axis: MEK activation induces HIF-1α expression, which increases FECH activity and thereby converts protoporphyrin IX (PpIX) to heme, reducing PpIX accumulation in cancer cells; MEK inhibition reduces HIF-1α and diminishes FECH activity.","method":"MEK inhibitor treatment, HIF-1α knockdown, FECH activity assay, RasV12-transformed cell and transgenic mouse models","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis with FECH activity readout in multiple models","pmids":["33335181"],"is_preprint":false},{"year":2022,"finding":"FECH is a direct molecular target of the flavonoid 4,4'-dimethoxychalcone (DMC): DMC inhibits FECH enzymatic activity (confirmed by thermal proteome profiling and enzymatic assay), which, together with Nrf2/HMOX1 pathway activation, leads to iron overload and ferroptosis in cancer cells.","method":"Thermal proteome profiling (TPP) target identification, FECH enzymatic activity assay, FECH knockdown, ferroptosis markers","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 1–2 — enzymatic activity assay with chemical target validation by TPP, supported by genetic knockdown","pmids":["35697292"],"is_preprint":false},{"year":1991,"finding":"The human ferrochelatase gene (FECH) maps to chromosome 18q22, establishing the chromosomal locus for the enzyme and for erythropoietic protoporphyria.","method":"Chromosomal hybridization of cDNA to sorted chromosomes; fluorescent in situ hybridization with a genomic clone","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — direct cytogenetic mapping, foundational chromosomal localization","pmids":["1783383"],"is_preprint":false},{"year":2024,"finding":"Loss of ferrochelatase (fech knockout via CRISPR/Cas9) in zebrafish larvae causes protoporphyrin IX accumulation, morphological defects, apoptosis (elevated bax/bcl2 ratio), and increased macrophage/neutrophil production, confirming that fech is required for PPIX clearance and its deficiency triggers innate immune activation and intrinsic apoptosis in vivo.","method":"CRISPR/Cas9 knockout zebrafish model, fluorescence imaging of PPIX, acridine orange apoptosis staining, qRT-PCR, neutral red/Sudan black immune cell staining","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with multiple defined cellular phenotype readouts in a vertebrate model","pmids":["39409147"],"is_preprint":false}],"current_model":"FECH encodes ferrochelatase, a homodimeric mitochondrial membrane-associated enzyme that catalyzes the terminal step of heme biosynthesis by inserting ferrous iron—delivered by frataxin—into protoporphyrin IX to form heme; its active site is formed at a hydrophobic membrane-proximal lip and contains two [2Fe-2S] clusters, its expression is transcriptionally regulated by c-Myc binding to promoter E-boxes and post-transcriptionally by NMD-mediated decay of a hypomorphic misspliced transcript, its activity is regulated downstream of the HIF-1α–MEK axis, and its inhibition (genetic or chemical) causes protoporphyrin IX accumulation, iron overload, and ferroptosis."},"narrative":{"teleology":[{"year":1975,"claim":"Establishing ferrochelatase as the primary enzymatic defect in erythropoietic protoporphyria resolved the molecular basis of PPIX accumulation and photosensitivity in EPP patients.","evidence":"Radiochemical enzyme assay (59Fe incorporation into porphyrin) in liver biopsies and cultured fibroblasts from EPP patients versus controls","pmids":["1184741"],"confidence":"High","gaps":["Gene not yet cloned; molecular identity of enzyme unknown","Mechanism of catalysis unresolved","Inheritance pattern and genetic modifiers not defined"]},{"year":1991,"claim":"Mapping the FECH gene to chromosome 18q22 provided the chromosomal foundation for genetic analysis of EPP and mutation screening.","evidence":"cDNA hybridization to sorted chromosomes and FISH with a genomic clone","pmids":["1783383"],"confidence":"High","gaps":["No mutations in EPP families yet identified at this locus","Three-dimensional structure of the enzyme unknown"]},{"year":2001,"claim":"The high-resolution crystal structure of human ferrochelatase revealed the homodimeric architecture, two [2Fe-2S] clusters, and a membrane-proximal hydrophobic lip forming the active-site entrance, providing a structural framework for catalysis.","evidence":"X-ray crystallography at 2.0 Å with iron anomalous scattering","pmids":["11175906"],"confidence":"High","gaps":["Iron donor delivering Fe²⁺ to the active site not identified","Role of [2Fe-2S] clusters in catalysis versus structural integrity unclear","No substrate-bound structure available"]},{"year":2001,"claim":"Discovery that a common intronic SNP (IVS3-48T/C) generates an aberrant splice site whose transcript is degraded by NMD explained how a hypomorphic trans allele modulates EPP penetrance, answering why heterozygous loss-of-function mutations show variable clinical expression.","evidence":"Haplotype segregation in EPP families, aberrant splice-site characterization, NMD demonstration","pmids":["11753383"],"confidence":"High","gaps":["Quantitative relationship between residual FECH activity threshold and clinical phenotype not precisely defined","Whether other cis-regulatory variants similarly modulate expression not explored"]},{"year":2004,"claim":"Identification of frataxin as the direct ferrous iron donor to ferrochelatase linked the heme biosynthesis pathway to Friedreich ataxia biology and explained how mitochondrial iron is channeled to the active site.","evidence":"In vitro reconstitution of iron delivery from holofrataxin to ferrochelatase, pulldown and affinity measurements","pmids":["15123683"],"confidence":"High","gaps":["Structural basis of the frataxin–ferrochelatase interaction not resolved","Whether alternative iron donors exist in vivo not excluded"]},{"year":2011,"claim":"Demonstrating that c-Myc binds E-boxes in the FECH promoter and that CpG demethylation at these sites promotes c-Myc/Max-driven transcription revealed how FECH expression is coupled to erythroid differentiation signals.","evidence":"ChIP, promoter methylation analysis, nuclear fractionation, siRNA knockdown in erythroid cell models","pmids":["21903580"],"confidence":"Medium","gaps":["Contribution of c-Myc regulation relative to other transcription factors (e.g., GATA-1) not compared","In vivo validation in primary erythroid progenitors lacking"]},{"year":2020,"claim":"Placing FECH activity downstream of a Ras/MEK–HIF-1α signaling axis established that oncogenic signaling can co-opt heme biosynthesis to manage PPIX levels in cancer cells.","evidence":"MEK inhibitor treatment, HIF-1α knockdown, FECH activity assay in RasV12-transformed cells and transgenic mouse models","pmids":["33335181"],"confidence":"Medium","gaps":["Whether HIF-1α regulates FECH transcriptionally or post-translationally not resolved","Generalizability beyond Ras-driven tumors untested"]},{"year":2022,"claim":"Identification of FECH as the direct target of the flavonoid DMC showed that chemical FECH inhibition causes iron overload and ferroptosis, linking heme pathway disruption to a regulated cell death modality.","evidence":"Thermal proteome profiling target identification, enzymatic activity assay, FECH knockdown, ferroptosis marker quantification","pmids":["35697292"],"confidence":"Medium","gaps":["Binding site of DMC on FECH not structurally defined","Whether ferroptosis is a direct consequence of PPIX accumulation or iron dyshomeostasis not disentangled"]},{"year":2024,"claim":"CRISPR knockout of fech in zebrafish confirmed that complete loss of ferrochelatase triggers PPIX accumulation, intrinsic apoptosis, and innate immune cell expansion in vivo, extending the phenotypic consequences beyond erythroid lineages.","evidence":"CRISPR/Cas9 fech knockout zebrafish, fluorescence PPIX imaging, apoptosis staining, qRT-PCR, immune cell staining","pmids":["39409147"],"confidence":"Medium","gaps":["Mechanism linking PPIX accumulation to macrophage/neutrophil expansion not defined","Whether immune activation is cell-autonomous or secondary to tissue damage unclear"]},{"year":null,"claim":"Key unresolved questions include the precise catalytic role of the [2Fe-2S] clusters, the structural basis of frataxin–ferrochelatase iron transfer, and how PPIX accumulation drives innate immune activation.","evidence":"","pmids":[],"confidence":"High","gaps":["No substrate-bound or frataxin-complexed structure of human ferrochelatase available","Functional role of [2Fe-2S] clusters (catalytic vs. structural vs. sensing) unresolved","Signaling pathway from PPIX accumulation to immune cell expansion not characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0016829","term_label":"lyase activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[1,3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":["FXN"],"other_free_text":[]},"mechanistic_narrative":"FECH encodes ferrochelatase, the homodimeric mitochondrial membrane-associated enzyme that catalyzes the terminal step of heme biosynthesis by inserting ferrous iron into protoporphyrin IX (PPIX) to form heme, with ferrous iron delivered directly by frataxin [PMID:1184741, PMID:15123683]. The 2.0 Å crystal structure reveals two [2Fe-2S] clusters and a hydrophobic lip that mediates inner mitochondrial membrane association and forms the entrance to the catalytic pocket [PMID:11175906]. FECH expression is transcriptionally regulated by c-Myc binding to promoter E-boxes and post-transcriptionally by nonsense-mediated decay of a misspliced transcript generated by a common intronic hypomorphic SNP (IVS3-48T/C), which modulates penetrance of dominant erythropoietic protoporphyria (EPP) [PMID:11753383, PMID:21903580]. Loss of FECH activity—whether by genetic mutation, gene knockout, or chemical inhibition—causes PPIX accumulation, triggers apoptosis and innate immune activation, and can induce iron overload and ferroptosis [PMID:1184741, PMID:39409147, PMID:35697292]."},"prefetch_data":{"uniprot":{"accession":"P22830","full_name":"Ferrochelatase, mitochondrial","aliases":["Heme synthase","Protoheme ferro-lyase"],"length_aa":423,"mass_kda":47.9,"function":"Catalyzes the ferrous insertion into protoporphyrin IX and participates in the terminal step in the heme biosynthetic pathway","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P22830/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/FECH","classification":"Common Essential","n_dependent_lines":520,"n_total_lines":1208,"dependency_fraction":0.4304635761589404},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CALM1","stoichiometry":0.2},{"gene":"CALM2","stoichiometry":0.2},{"gene":"CALM3","stoichiometry":0.2},{"gene":"DNAJB6","stoichiometry":0.2},{"gene":"MINK1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/FECH","total_profiled":1310},"omim":[{"mim_id":"616860","title":"ANEMIA, SIDEROBLASTIC, 3, PYRIDOXINE-REFRACTORY; SIDBA3","url":"https://www.omim.org/entry/616860"},{"mim_id":"615317","title":"IRON-SULFUR CLUSTER ASSEMBLY 2; ISCA2","url":"https://www.omim.org/entry/615317"},{"mim_id":"615316","title":"IRON-SULFUR CLUSTER ASSEMBLY FACTOR IBA57; IBA57","url":"https://www.omim.org/entry/615316"},{"mim_id":"614981","title":"ATPase INHIBITORY FACTOR 1; ATPIF1","url":"https://www.omim.org/entry/614981"},{"mim_id":"612386","title":"FERROCHELATASE; FECH","url":"https://www.omim.org/entry/612386"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":36.8}],"url":"https://www.proteinatlas.org/search/FECH"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P22830","domains":[{"cath_id":"3.40.50.1400","chopping":"70-229_375-421","consensus_level":"medium","plddt":96.4769,"start":70,"end":421},{"cath_id":"3.40.50.1400","chopping":"232-368","consensus_level":"medium","plddt":97.8447,"start":232,"end":368}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P22830","model_url":"https://alphafold.ebi.ac.uk/files/AF-P22830-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P22830-F1-predicted_aligned_error_v6.png","plddt_mean":86.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FECH","jax_strain_url":"https://www.jax.org/strain/search?query=FECH"},"sequence":{"accession":"P22830","fasta_url":"https://rest.uniprot.org/uniprotkb/P22830.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P22830/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P22830"}},"corpus_meta":[{"pmid":"11753383","id":"PMC_11753383","title":"The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11753383","citation_count":196,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35697292","id":"PMC_35697292","title":"Flavonoid 4,4'-dimethoxychalcone induced ferroptosis in cancer cells by synergistically activating Keap1/Nrf2/HMOX1 pathway and inhibiting FECH.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35697292","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1783383","id":"PMC_1783383","title":"Assignment of the human ferrochelatase gene (FECH) and a locus for protoporphyria to chromosome 18q22.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1783383","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17597821","id":"PMC_17597821","title":"Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17597821","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33335181","id":"PMC_33335181","title":"MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33335181","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21903580","id":"PMC_21903580","title":"5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21903580","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8034322","id":"PMC_8034322","title":"Molecular analysis of functional and nonfunctional genes for human ferrochelatase: isolation and characterization of a FECH pseudogene and its sublocalization on chromosome 3.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8034322","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31273344","id":"PMC_31273344","title":"Targeted resequencing of FECH locus reveals that a novel deep intronic pathogenic variant and eQTLs may cause erythropoietic protoporphyria (EPP) through a methylation-dependent mechanism.","date":"2019","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31273344","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34686726","id":"PMC_34686726","title":"Nkx3-1 and Fech genes might be switch genes involved in pituitary non-functioning adenoma invasiveness.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34686726","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20337824","id":"PMC_20337824","title":"A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma.","date":"2010","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/20337824","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35470464","id":"PMC_35470464","title":"The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury.","date":"2022","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35470464","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17888693","id":"PMC_17888693","title":"A 10376 bp deletion of FECH gene responsible for erythropoietic protoporphyria.","date":"2007","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17888693","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24751349","id":"PMC_24751349","title":"Comparative uptake of ¹⁸F-FEN-DPAZn2, ¹⁸F-FECH, ¹⁸F-fluoride, and ¹⁸F-FDG in fibrosarcoma and aseptic inflammation.","date":"2014","source":"Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24751349","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29941360","id":"PMC_29941360","title":"Digital PCR (dPCR) analysis reveals that the homozygous c.315-48T>C variant in the FECH gene might cause erythropoietic protoporphyria (EPP).","date":"2018","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29941360","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34553073","id":"PMC_34553073","title":"Down-regulation of IGHG1 enhances Protoporphyrin IX accumulation and inhibits hemin biosynthesis in colorectal cancer by suppressing the MEK-FECH axis.","date":"2021","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34553073","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19055472","id":"PMC_19055472","title":"A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19055472","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19888946","id":"PMC_19888946","title":"A novel splicing mutation and haplotype analysis of the FECH gene in a Chinese family with erythropoietic protoporphyria.","date":"2009","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/19888946","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39409147","id":"PMC_39409147","title":"CRISPR/Cas9-Mediated fech Knockout Zebrafish: Unraveling the Pathogenesis of Erythropoietic Protoporphyria and Facilitating Drug Screening.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39409147","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26789144","id":"PMC_26789144","title":"A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease.","date":"2015","source":"Folia biologica","url":"https://pubmed.ncbi.nlm.nih.gov/26789144","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27704751","id":"PMC_27704751","title":"Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review.","date":"2016","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/27704751","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31304091","id":"PMC_31304091","title":"Characterization of a novel pathogenic variant in the FECH gene associated with erythropoietic protoporphyria.","date":"2019","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/31304091","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21659066","id":"PMC_21659066","title":"Erythropoietic protoporphyria: a family study and report of a novel mutation in the FECH gene.","date":"2011","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/21659066","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40582371","id":"PMC_40582371","title":"Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug-Induced Liver Injury in China.","date":"2025","source":"Fundamental & clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40582371","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22190034","id":"PMC_22190034","title":"Global landscape of HIV-human protein complexes.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22190034","citation_count":593,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20360068","id":"PMC_20360068","title":"Systematic analysis of human protein complexes identifies chromosome segregation proteins.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20360068","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31056398","id":"PMC_31056398","title":"Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31056398","citation_count":298,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26058080","id":"PMC_26058080","title":"Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26058080","citation_count":293,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28611215","id":"PMC_28611215","title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28611215","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1184741","id":"PMC_1184741","title":"Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts.","date":"1975","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1184741","citation_count":232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15123683","id":"PMC_15123683","title":"Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15123683","citation_count":226,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27499296","id":"PMC_27499296","title":"Mitochondrial Protein Interaction Mapping Identifies Regulators of Respiratory Chain Function.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27499296","citation_count":220,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27173435","id":"PMC_27173435","title":"An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27173435","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11175906","id":"PMC_11175906","title":"The 2.0 A structure of human ferrochelatase, the terminal enzyme of heme biosynthesis.","date":"2001","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/11175906","citation_count":181,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25544563","id":"PMC_25544563","title":"Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25544563","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22114354","id":"PMC_22114354","title":"MINOS1 is a conserved component of mitofilin complexes and required for mitochondrial function and cristae organization.","date":"2011","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22114354","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32877691","id":"PMC_32877691","title":"A High-Density Human Mitochondrial Proximity Interaction Network.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32877691","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12475,"output_tokens":2031,"usd":0.033945},"stage2":{"model":"claude-opus-4-6","input_tokens":5338,"output_tokens":2178,"usd":0.12171},"total_usd":0.338893,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":23879,"output_tokens":2201,"usd":0.052326},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":5780,"output_tokens":2335,"usd":0.130912}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"An intronic SNP (IVS3-48T/C) in the FECH gene modulates use of a constitutive aberrant acceptor splice site; the aberrantly spliced mRNA is degraded by nonsense-mediated decay (NMD), reducing steady-state FECH mRNA and enzyme levels, which together with a null allele produces the EPP phenotype.\",\n      \"method\": \"Haplotype segregation analysis, RNA analysis, NMD mechanism characterization\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (haplotype analysis, RNA quantification, NMD characterization), highly cited foundational paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"11753383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The flavonoid DMC directly inhibits the enzymatic activity of FECH (ferrochelatase), identified by thermal proteome profiling; FECH inhibition combined with HMOX1 upregulation causes iron overload and triggers ferroptosis in cancer cells.\",\n      \"method\": \"Thermal proteome profiling (TPP) target identification, enzymatic activity assay, knockdown/overexpression with ferroptosis readout\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — thermal proteome profiling plus enzymatic activity assay and functional cellular readout, single lab\",\n      \"pmids\": [\"35697292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The transcription factor c-Myc binds to E-boxes in the FECH promoter to regulate ferrochelatase expression and heme biosynthesis; 5-aza-2'-deoxycytidine promotes nuclear translocation of c-Myc and its binding to Max, increasing FECH transcription and iron incorporation into heme.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter methylation analysis, nuclear fractionation, erythroid cell differentiation models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and functional promoter analysis with nuclear translocation assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21903580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HIF-1α acts downstream of the Ras/MEK pathway to regulate FECH activity; MEK inhibition reduces HIF-1α expression, which in turn decreases FECH activity and increases protoporphyrin IX (PpIX) accumulation in cancer cells.\",\n      \"method\": \"MEK inhibitor treatment, HIF-1α inhibition, FECH activity assay, PpIX fluorescence quantification in RasV12-transformed cells and HRAS transgenic mice\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic activity assay combined with genetic and pharmacological perturbations in both cell lines and transgenic mice, single lab\",\n      \"pmids\": [\"33335181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IGHG1 knockdown reduces phosphorylated ERK and FECH expression in colorectal cancer cells, demonstrating that IGHG1 regulates hemin biosynthesis and PpIX accumulation through the MEK-FECH axis.\",\n      \"method\": \"shRNA-mediated knockdown, western blot for p-ERK and FECH, PpIX fluorescence and hemin content assay\",\n      \"journal\": \"Open life sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single knockdown approach with limited mechanistic dissection of FECH-specific pathway\",\n      \"pmids\": [\"34553073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A novel deep intronic FECH variant abolishes an exonic splicing silencer site and creates a new methylated CpG dinucleotide, leading to pseudo-exon insertion with a stop codon in mature FECH transcript, establishing methylation-dependent modulation of pre-mRNA splicing as a mechanism controlling FECH expression.\",\n      \"method\": \"High-throughput resequencing, qualitative RNA analysis, quantitative DNA methylation analysis\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA splicing analysis combined with methylation quantification and genetic characterization, multiple orthogonal methods in single study\",\n      \"pmids\": [\"31273344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A 10,376 bp deletion encompassing the FECH promoter, exon 1, and part of intron 1 abolishes gene expression from the mutant allele, as demonstrated by RNA analysis showing 50% reduction in ferrochelatase mRNA in heterozygous carriers.\",\n      \"method\": \"Long-PCR, SNP analysis, RNA expression analysis\",\n      \"journal\": \"Blood cells, molecules & diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA analysis confirms loss of promoter-driven expression, mechanistically explaining allele-specific silencing\",\n      \"pmids\": [\"17888693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Digital PCR quantification demonstrates that the IVS3-48T>C (c.315-48T>C) variant directly increases the proportion of aberrantly spliced FECH mRNA; homozygosity for this variant doubles the aberrant splicing frequency and is itself pathological, establishing the molecular threshold mechanism for EPP.\",\n      \"method\": \"Digital PCR (dPCR) for absolute quantification of aberrantly spliced mRNA molecules\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative molecular analysis establishing dose-response relationship between variant and aberrant splicing, single lab\",\n      \"pmids\": [\"29941360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRISPR/Cas9-mediated fech knockout in zebrafish recapitulates EPP pathology including PPIX accumulation, apoptosis (elevated bax/bcl2 ratio), and innate immune activation (macrophage and neutrophil expansion), establishing fech's role in heme biosynthesis and its loss-of-function consequences in vivo.\",\n      \"method\": \"CRISPR/Cas9 knockout, fluorescence quantification of PPIX, acridine orange staining for apoptosis, qRT-PCR, neutral red and Sudan black staining\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout in vertebrate model with multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"39409147\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FECH (ferrochelatase) catalyzes the terminal step of heme biosynthesis by inserting ferrous iron into protoporphyrin IX; its expression is regulated transcriptionally by c-Myc binding to promoter E-boxes and post-transcriptionally by an intronic SNP (IVS3-48T/C) that promotes aberrant splicing subject to nonsense-mediated decay, while its enzymatic activity is regulated downstream of the HIF-1α/MEK signaling axis, and loss of function causes protoporphyrin IX accumulation leading to the photosensitivity and liver damage characteristic of erythropoietic protoporphyria.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1975,\n      \"finding\": \"Ferrochelatase (heme synthetase) catalyzes the terminal step of heme biosynthesis—chelation of ferrous iron with porphyrin—and its activity is markedly deficient in liver and cultured skin fibroblasts of patients with erythropoietic protoporphyria, establishing deficient ferrochelatase as the primary enzymatic defect in protoporphyria.\",\n      \"method\": \"Radiochemical enzyme assay using 59Fe and deuteroporphyrin/protoporphyrin as substrates in liver biopsies and skin fibroblast sonicates\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay, replicated across liver and fibroblast tissues from multiple patients vs. controls\",\n      \"pmids\": [\"1184741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human ferrochelatase is a homodimeric (86 kDa) mitochondrial membrane-associated enzyme whose 2.0 Å crystal structure reveals two [2Fe-2S] clusters, a 12-residue hydrophobic lip mediating membrane association that also forms the entrance to the active site pocket, and a conserved active site geometry supporting a catalytic model for ferrous iron insertion into protoporphyrin IX to form heme.\",\n      \"method\": \"X-ray crystallography at 2.0 Å resolution using single-wavelength iron anomalous scattering\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional interpretation supported by prior biochemical studies\",\n      \"pmids\": [\"11175906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The penetrance of dominant erythropoietic protoporphyria is modulated by a hypomorphic FECH allele: an intronic SNP (IVS3-48T/C) activates an aberrant splice acceptor site, generating a misspliced mRNA that is degraded by nonsense-mediated decay (NMD), thereby reducing steady-state FECH mRNA and enzyme levels below the threshold required for clinical expression.\",\n      \"method\": \"Haplotype segregation analysis, identification of aberrant splice site usage, NMD mechanism characterization\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — molecular dissection of splicing mechanism plus NMD, independently replicated in subsequent studies\",\n      \"pmids\": [\"11753383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human frataxin (holofrataxin) is a high-affinity iron-binding partner of ferrochelatase that directly delivers ferrous iron to ferrochelatase to mediate the terminal step of mitochondrial heme biosynthesis; distinct binding affinities of holofrataxin for ferrochelatase versus the ISU scaffold protein allow discrimination between heme and iron-sulfur cluster biosynthesis pathways.\",\n      \"method\": \"Protein–protein interaction (pulldown/reconstitution), iron delivery assay in vitro, affinity measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of iron delivery with binding-affinity characterization\",\n      \"pmids\": [\"15123683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The transcription factor c-Myc regulates FECH gene expression by binding to E-boxes in the FECH promoter; 5-aza-2'-deoxycytidine demethylates these E-box-containing CpG sites and promotes nuclear translocation of c-Myc and its heterodimerization with Max, thereby increasing FECH transcription, heme biosynthesis, and erythroid differentiation.\",\n      \"method\": \"Promoter methylation analysis, ChIP, nuclear fractionation, siRNA knockdown in erythroid cell models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, methylation analysis, nuclear translocation) in a single lab\",\n      \"pmids\": [\"21903580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The Ras/MEK signaling pathway suppresses FECH activity through a HIF-1α-dependent axis: MEK activation induces HIF-1α expression, which increases FECH activity and thereby converts protoporphyrin IX (PpIX) to heme, reducing PpIX accumulation in cancer cells; MEK inhibition reduces HIF-1α and diminishes FECH activity.\",\n      \"method\": \"MEK inhibitor treatment, HIF-1α knockdown, FECH activity assay, RasV12-transformed cell and transgenic mouse models\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis with FECH activity readout in multiple models\",\n      \"pmids\": [\"33335181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FECH is a direct molecular target of the flavonoid 4,4'-dimethoxychalcone (DMC): DMC inhibits FECH enzymatic activity (confirmed by thermal proteome profiling and enzymatic assay), which, together with Nrf2/HMOX1 pathway activation, leads to iron overload and ferroptosis in cancer cells.\",\n      \"method\": \"Thermal proteome profiling (TPP) target identification, FECH enzymatic activity assay, FECH knockdown, ferroptosis markers\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic activity assay with chemical target validation by TPP, supported by genetic knockdown\",\n      \"pmids\": [\"35697292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The human ferrochelatase gene (FECH) maps to chromosome 18q22, establishing the chromosomal locus for the enzyme and for erythropoietic protoporphyria.\",\n      \"method\": \"Chromosomal hybridization of cDNA to sorted chromosomes; fluorescent in situ hybridization with a genomic clone\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct cytogenetic mapping, foundational chromosomal localization\",\n      \"pmids\": [\"1783383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of ferrochelatase (fech knockout via CRISPR/Cas9) in zebrafish larvae causes protoporphyrin IX accumulation, morphological defects, apoptosis (elevated bax/bcl2 ratio), and increased macrophage/neutrophil production, confirming that fech is required for PPIX clearance and its deficiency triggers innate immune activation and intrinsic apoptosis in vivo.\",\n      \"method\": \"CRISPR/Cas9 knockout zebrafish model, fluorescence imaging of PPIX, acridine orange apoptosis staining, qRT-PCR, neutral red/Sudan black immune cell staining\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotype readouts in a vertebrate model\",\n      \"pmids\": [\"39409147\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FECH encodes ferrochelatase, a homodimeric mitochondrial membrane-associated enzyme that catalyzes the terminal step of heme biosynthesis by inserting ferrous iron—delivered by frataxin—into protoporphyrin IX to form heme; its active site is formed at a hydrophobic membrane-proximal lip and contains two [2Fe-2S] clusters, its expression is transcriptionally regulated by c-Myc binding to promoter E-boxes and post-transcriptionally by NMD-mediated decay of a hypomorphic misspliced transcript, its activity is regulated downstream of the HIF-1α–MEK axis, and its inhibition (genetic or chemical) causes protoporphyrin IX accumulation, iron overload, and ferroptosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FECH (ferrochelatase) catalyzes the terminal step of heme biosynthesis by inserting ferrous iron into protoporphyrin IX, and its loss of function causes protoporphyrin IX accumulation, apoptosis, and innate immune activation characteristic of erythropoietic protoporphyria (EPP) [PMID:39409147, PMID:11753383]. FECH expression is controlled transcriptionally by c-Myc binding to E-boxes in its promoter [PMID:21903580] and post-transcriptionally by an intronic polymorphism (IVS3-48T>C) that promotes aberrant splicing subject to nonsense-mediated decay, with the degree of aberrant splicing proportional to variant dosage [PMID:11753383, PMID:29941360]. FECH enzymatic activity is regulated downstream of the Ras/MEK/HIF-1α signaling axis, where MEK inhibition reduces HIF-1α-dependent FECH activity and increases protoporphyrin IX levels in cancer cells [PMID:33335181].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the long-standing question of how the common low-expression FECH allele reduces enzyme levels: the IVS3-48T>C polymorphism enhances use of a constitutive aberrant splice site, and the resulting mRNA is degraded by nonsense-mediated decay, establishing the two-hit molecular basis of EPP.\",\n      \"evidence\": \"Haplotype segregation, RNA analysis, and NMD characterization in EPP families\",\n      \"pmids\": [\"11753383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise quantitative relationship between variant dosage and aberrant splicing was not yet established\",\n        \"Whether additional cis-regulatory elements modify the splicing effect was unknown\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated that large genomic deletions encompassing the FECH promoter and exon 1 abolish allele-specific transcription, expanding the mutational spectrum beyond point mutations and splice-site variants.\",\n      \"evidence\": \"Long-PCR and SNP-based allele-specific RNA analysis in heterozygous carriers\",\n      \"pmids\": [\"17888693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Frequency of such large deletions among EPP patients was not defined\",\n        \"Whether partial promoter deletions yield intermediate expression was untested\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified c-Myc as a direct transcriptional activator of FECH through E-box binding, linking heme biosynthesis regulation to a major proliferative transcription factor and showing that promoter methylation status controls c-Myc access.\",\n      \"evidence\": \"ChIP, promoter methylation analysis, and nuclear fractionation in erythroid cell differentiation models\",\n      \"pmids\": [\"21903580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether c-Myc regulation of FECH is physiologically relevant during erythropoiesis in vivo was not demonstrated\",\n        \"Other transcription factors cooperating at the FECH promoter were not characterized\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Quantitatively established that the IVS3-48T>C variant operates in a dosage-dependent manner, with homozygosity doubling the proportion of aberrantly spliced FECH mRNA, defining the molecular threshold mechanism for EPP disease expression.\",\n      \"evidence\": \"Digital PCR absolute quantification of aberrantly spliced mRNA\",\n      \"pmids\": [\"29941360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether tissue-specific splicing factors modulate the threshold was not addressed\",\n        \"The precise residual FECH activity sufficient to prevent EPP symptoms was not defined\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a novel pathogenic mechanism whereby a deep intronic variant creates a methylation-sensitive pseudo-exon in FECH, demonstrating that CpG methylation status can directly modulate pre-mRNA splicing fidelity.\",\n      \"evidence\": \"High-throughput resequencing, qualitative RNA analysis, and quantitative DNA methylation profiling\",\n      \"pmids\": [\"31273344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether methylation-dependent pseudo-exon insertion varies across tissues or developmental stages was not tested\",\n        \"The frequency of such deep intronic methylation-sensitive variants in other EPP patients is unknown\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed FECH activity under the control of the Ras/MEK/HIF-1α signaling axis, showing that oncogenic signaling sustains FECH activity and that its pharmacological disruption causes protoporphyrin IX accumulation in cancer cells.\",\n      \"evidence\": \"MEK and HIF-1α inhibitor treatment with FECH activity assays and PpIX quantification in RasV12-transformed cells and HRAS transgenic mice\",\n      \"pmids\": [\"33335181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HIF-1α regulates FECH transcriptionally or post-translationally was not resolved\",\n        \"Relevance of this axis to normal erythroid heme production was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified FECH as a direct target of the flavonoid DMC, showing that pharmacological FECH inhibition synergizes with HMOX1 upregulation to cause iron overload and ferroptosis in cancer cells.\",\n      \"evidence\": \"Thermal proteome profiling target identification, enzymatic activity assay, and knockdown/overexpression with ferroptosis readouts\",\n      \"pmids\": [\"35697292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The binding site of DMC on FECH and structural basis of inhibition are unknown\",\n        \"Whether this ferroptosis mechanism operates in non-cancer cells was not examined\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CRISPR knockout in zebrafish confirmed that FECH loss of function recapitulates the full EPP phenotype including PPIX accumulation, elevated apoptosis, and innate immune cell expansion, establishing FECH as necessary for heme-dependent immune homeostasis in vivo.\",\n      \"evidence\": \"CRISPR/Cas9 fech knockout in zebrafish with fluorescence, apoptosis, and immune cell quantification\",\n      \"pmids\": [\"39409147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the immune activation is a direct consequence of PPIX phototoxicity or heme deficiency was not distinguished\",\n        \"Mammalian in vivo validation of the immune phenotype is lacking\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for FECH regulation by the HIF-1α/MEK axis, the identity of tissue-specific splicing factors that modulate the IVS3-48T>C aberrant splice threshold, and the precise residual FECH activity needed to prevent EPP remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model explains how HIF-1α signaling modulates FECH protein activity\",\n        \"Splicing regulatory factors governing the aberrant acceptor site in intron 3 are unidentified\",\n        \"Genotype-to-phenotype thresholds for residual FECH activity in different tissues are undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0016740\",\n        \"supporting_discovery_ids\": [1, 3, 8]\n      }\n    ],\n    \"localization\": [\n      {\n        \"term_id\": \"GO:0005739\",\n        \"supporting_discovery_ids\": [8]\n      }\n    ],\n    \"pathway\": [\n      {\n        \"term_id\": \"R-HSA-1430728\",\n        \"supporting_discovery_ids\": [0, 1, 2, 3, 8]\n      },\n      {\n        \"term_id\": \"R-HSA-1643685\",\n        \"supporting_discovery_ids\": [0, 5, 7, 8]\n      }\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MYC\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"FECH encodes ferrochelatase, the homodimeric mitochondrial membrane-associated enzyme that catalyzes the terminal step of heme biosynthesis by inserting ferrous iron into protoporphyrin IX (PPIX) to form heme, with ferrous iron delivered directly by frataxin [PMID:1184741, PMID:15123683]. The 2.0 Å crystal structure reveals two [2Fe-2S] clusters and a hydrophobic lip that mediates inner mitochondrial membrane association and forms the entrance to the catalytic pocket [PMID:11175906]. FECH expression is transcriptionally regulated by c-Myc binding to promoter E-boxes and post-transcriptionally by nonsense-mediated decay of a misspliced transcript generated by a common intronic hypomorphic SNP (IVS3-48T/C), which modulates penetrance of dominant erythropoietic protoporphyria (EPP) [PMID:11753383, PMID:21903580]. Loss of FECH activity—whether by genetic mutation, gene knockout, or chemical inhibition—causes PPIX accumulation, triggers apoptosis and innate immune activation, and can induce iron overload and ferroptosis [PMID:1184741, PMID:39409147, PMID:35697292].\",\n  \"teleology\": [\n    {\n      \"year\": 1975,\n      \"claim\": \"Establishing ferrochelatase as the primary enzymatic defect in erythropoietic protoporphyria resolved the molecular basis of PPIX accumulation and photosensitivity in EPP patients.\",\n      \"evidence\": \"Radiochemical enzyme assay (59Fe incorporation into porphyrin) in liver biopsies and cultured fibroblasts from EPP patients versus controls\",\n      \"pmids\": [\"1184741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Gene not yet cloned; molecular identity of enzyme unknown\",\n        \"Mechanism of catalysis unresolved\",\n        \"Inheritance pattern and genetic modifiers not defined\"\n      ]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Mapping the FECH gene to chromosome 18q22 provided the chromosomal foundation for genetic analysis of EPP and mutation screening.\",\n      \"evidence\": \"cDNA hybridization to sorted chromosomes and FISH with a genomic clone\",\n      \"pmids\": [\"1783383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No mutations in EPP families yet identified at this locus\",\n        \"Three-dimensional structure of the enzyme unknown\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The high-resolution crystal structure of human ferrochelatase revealed the homodimeric architecture, two [2Fe-2S] clusters, and a membrane-proximal hydrophobic lip forming the active-site entrance, providing a structural framework for catalysis.\",\n      \"evidence\": \"X-ray crystallography at 2.0 Å with iron anomalous scattering\",\n      \"pmids\": [\"11175906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Iron donor delivering Fe²⁺ to the active site not identified\",\n        \"Role of [2Fe-2S] clusters in catalysis versus structural integrity unclear\",\n        \"No substrate-bound structure available\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that a common intronic SNP (IVS3-48T/C) generates an aberrant splice site whose transcript is degraded by NMD explained how a hypomorphic trans allele modulates EPP penetrance, answering why heterozygous loss-of-function mutations show variable clinical expression.\",\n      \"evidence\": \"Haplotype segregation in EPP families, aberrant splice-site characterization, NMD demonstration\",\n      \"pmids\": [\"11753383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Quantitative relationship between residual FECH activity threshold and clinical phenotype not precisely defined\",\n        \"Whether other cis-regulatory variants similarly modulate expression not explored\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of frataxin as the direct ferrous iron donor to ferrochelatase linked the heme biosynthesis pathway to Friedreich ataxia biology and explained how mitochondrial iron is channeled to the active site.\",\n      \"evidence\": \"In vitro reconstitution of iron delivery from holofrataxin to ferrochelatase, pulldown and affinity measurements\",\n      \"pmids\": [\"15123683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the frataxin–ferrochelatase interaction not resolved\",\n        \"Whether alternative iron donors exist in vivo not excluded\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that c-Myc binds E-boxes in the FECH promoter and that CpG demethylation at these sites promotes c-Myc/Max-driven transcription revealed how FECH expression is coupled to erythroid differentiation signals.\",\n      \"evidence\": \"ChIP, promoter methylation analysis, nuclear fractionation, siRNA knockdown in erythroid cell models\",\n      \"pmids\": [\"21903580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Contribution of c-Myc regulation relative to other transcription factors (e.g., GATA-1) not compared\",\n        \"In vivo validation in primary erythroid progenitors lacking\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing FECH activity downstream of a Ras/MEK–HIF-1α signaling axis established that oncogenic signaling can co-opt heme biosynthesis to manage PPIX levels in cancer cells.\",\n      \"evidence\": \"MEK inhibitor treatment, HIF-1α knockdown, FECH activity assay in RasV12-transformed cells and transgenic mouse models\",\n      \"pmids\": [\"33335181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HIF-1α regulates FECH transcriptionally or post-translationally not resolved\",\n        \"Generalizability beyond Ras-driven tumors untested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of FECH as the direct target of the flavonoid DMC showed that chemical FECH inhibition causes iron overload and ferroptosis, linking heme pathway disruption to a regulated cell death modality.\",\n      \"evidence\": \"Thermal proteome profiling target identification, enzymatic activity assay, FECH knockdown, ferroptosis marker quantification\",\n      \"pmids\": [\"35697292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Binding site of DMC on FECH not structurally defined\",\n        \"Whether ferroptosis is a direct consequence of PPIX accumulation or iron dyshomeostasis not disentangled\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CRISPR knockout of fech in zebrafish confirmed that complete loss of ferrochelatase triggers PPIX accumulation, intrinsic apoptosis, and innate immune cell expansion in vivo, extending the phenotypic consequences beyond erythroid lineages.\",\n      \"evidence\": \"CRISPR/Cas9 fech knockout zebrafish, fluorescence PPIX imaging, apoptosis staining, qRT-PCR, immune cell staining\",\n      \"pmids\": [\"39409147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism linking PPIX accumulation to macrophage/neutrophil expansion not defined\",\n        \"Whether immune activation is cell-autonomous or secondary to tissue damage unclear\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise catalytic role of the [2Fe-2S] clusters, the structural basis of frataxin–ferrochelatase iron transfer, and how PPIX accumulation drives innate immune activation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No substrate-bound or frataxin-complexed structure of human ferrochelatase available\",\n        \"Functional role of [2Fe-2S] clusters (catalytic vs. structural vs. sensing) unresolved\",\n        \"Signaling pathway from PPIX accumulation to immune cell expansion not characterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0016829\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FXN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}